Nutra Pharma Corp (NPHC) Retained Earnings (2010 - 2026)

Nutra Pharma has disclosed Retained Earnings across 17 years of filings, most recently posting -$82.7 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 7.02% year-over-year to -$82.7 million; the TTM figure through Jun 2026 stood at -$82.7 million (down 7.02% YoY), while the FY2025 annual figure was -$78.3 million, down 2.69% from the prior year.
• Retained Earnings came in at -$82.7 million for Q2 2026 at Nutra Pharma, down from -$78.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$73.6 million in Q4 2022 to a low of -$82.7 million in Q2 2026.
• Average Retained Earnings over 5 years is -$76.6 million, with a median of -$76.5 million recorded in 2022.
• Year-over-year, Retained Earnings climbed 25.26% in 2022 and fell 7.02% in 2026.
• Over 5 years, Retained Earnings stood at -$73.6 million in 2022, then dropped by 1.89% to -$74.9 million in 2023, then decreased by 1.72% to -$76.2 million in 2024, then dropped by 2.69% to -$78.3 million in 2025, then slipped by 5.63% to -$82.7 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$82.7 million in Q2 2026, -$78.7 million in Q1 2026, and -$78.3 million in Q4 2025.